Psyence develops natural psilocybin products and treatment protocols specifically for managing anxiety and depression in palliative care settings. By utilizing a federally licensed cultivation facility, the company aims to provide safe and effective psychedelic therapies to address psychological trauma and mental health disorders.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients in palliative care settings often experience significant anxiety and depression, which can be difficult to manage with existing treatments. Current pharmaceutical options may have limited efficacy or undesirable side effects, highlighting the need for alternative therapeutic approaches.
Solution
Psyence develops natural psilocybin-based products and treatment protocols designed to alleviate anxiety and depression specifically within palliative care. The company operates a federally licensed psilocybin cultivation and production facility, ensuring a consistent supply of pharmaceutical-grade natural psilocybin. Psyence focuses on creating safe and effective psychedelic therapies to address the psychological trauma and mental health disorders associated with palliative care. Their approach includes medicinal formulations and structured treatment programs delivered in clinical environments.
Target Audience
The primary target audience includes patients in palliative care settings experiencing anxiety and depression, as well as the healthcare providers and clinical researchers who support them.
Features
- Natural psilocybin cultivation and production in a federally licensed, ISO22000 certified facility
- Development of standardized psilocybin-based medicinal formulations
- Clinical trial programs focused on anxiety and depression in palliative care
- Treatment protocols designed for integration into clinical settings